Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Nathalie Goemans, Eugenio Mercuri, Е. Д. Белоусова, et al.
Neuromuscular Disorders (2017) Vol. 28, Iss. 1, pp. 4-15
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Duchenne muscular dystrophy
Dongsheng Duan, Nathalie Goemans, Shin’ichi Takeda, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 830
Therapeutic developments for Duchenne muscular dystrophy
Ingrid E.C. Verhaart, Annemieke Aartsma‐Rus
Nature Reviews Neurology (2019) Vol. 15, Iss. 7, pp. 373-386
Closed Access | Times Cited: 335
Therapeutic Oligonucleotides: State of the Art
Smith Rjh, Rula Zain
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 605-630
Closed Access | Times Cited: 279
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Paula R. Clemens, Vamshi K. Rao, Anne M. Connolly, et al.
JAMA Neurology (2020) Vol. 77, Iss. 8, pp. 982-982
Open Access | Times Cited: 219
Emerging therapies for Duchenne muscular dystrophy
Theodora Markati, Maryam Oskoui, Michelle A. Farrar, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 9, pp. 814-829
Closed Access | Times Cited: 76
Unveiling Sequence-Agnostic Mixed-Chemical Modification Patterns for Splice-Switching Oligonucleotides using the NATURA platform
Tommaso Tabaglio, Taniya Agarwal, Wei Yuan Cher, et al.
Molecular Therapy — Nucleic Acids (2025) Vol. 36, Iss. 1, pp. 102422-102422
Open Access | Times Cited: 2
Exon-skipping advances for Duchenne muscular dystrophy
Lucía Echevarría, Philippine Aupy, Aurélie Goyenvalle
Human Molecular Genetics (2018) Vol. 27, Iss. R2, pp. R163-R172
Open Access | Times Cited: 103
Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy
Perry B. Shieh
Neurotherapeutics (2018) Vol. 15, Iss. 4, pp. 840-848
Open Access | Times Cited: 87
Muscle Wasting Diseases: Novel Targets and Treatments
Regula Furrer, Christoph Handschin
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 315-339
Open Access | Times Cited: 86
From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies
Hironori Adachi, Martin Hengesbach, Yi‐Tao Yu, et al.
Biomedicines (2021) Vol. 9, Iss. 5, pp. 550-550
Open Access | Times Cited: 58
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
F. Fortunato, Rachele Rossi, Maria Sofia Falzarano, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 820-820
Open Access | Times Cited: 57
Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS
Kandasamy Pachamuthu, Yuanjing Liu, Vincent Aduda, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 10, pp. 5401-5423
Open Access | Times Cited: 52
Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
Yusuke Echigoya, Kenji Rowel Q. Lim, Akinori Nakamura, et al.
Journal of Personalized Medicine (2018) Vol. 8, Iss. 4, pp. 41-41
Open Access | Times Cited: 77
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
M.K. Tsoumpra, Seiji Fukumoto, Toshio Matsumoto, et al.
EBioMedicine (2019) Vol. 45, pp. 630-645
Open Access | Times Cited: 75
MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy
Karin J. Naarding, Harmen Reyngoudt, Erik W. van Zwet, et al.
Neurology (2020) Vol. 94, Iss. 13
Open Access | Times Cited: 66
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials
Craig M. McDonald, Gautam Sajeev, Zhiwen Yao, et al.
Muscle & Nerve (2019) Vol. 61, Iss. 1, pp. 26-35
Open Access | Times Cited: 60
A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics
Kirsten Deprey, Nefeli Batistatou, Joshua A. Kritzer
Nucleic Acids Research (2020) Vol. 48, Iss. 14, pp. 7623-7639
Open Access | Times Cited: 55
Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials
Laurent Servais, Karl Yen, Maitea Guridi, et al.
Journal of Neuromuscular Diseases (2021) Vol. 9, Iss. 2, pp. 335-346
Open Access | Times Cited: 52
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy
Galina Filonova, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 2, pp. 133-143
Open Access | Times Cited: 17
Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
Vandana Ayyar Gupta, Jacqueline Pitchforth, Joana Domingos, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0283669-e0283669
Open Access | Times Cited: 17
Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology
Annemieke Aartsma‐Rus, Jennifer E. Morgan, Pallavi Lonkar, et al.
Journal of Neuromuscular Diseases (2019) Vol. 6, Iss. 1, pp. 147-159
Open Access | Times Cited: 51
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment
Olga Mitelman, Hoda Abdel‐Hamid, Barry J. Byrne, et al.
Journal of Neuromuscular Diseases (2021) Vol. 9, Iss. 1, pp. 39-52
Open Access | Times Cited: 38
Alternative Splicing in Cardiovascular Disease—A Survey of Recent Findings
Ena Hašimbegović, Victor Schweiger, Nina Kastner, et al.
Genes (2021) Vol. 12, Iss. 9, pp. 1457-1457
Open Access | Times Cited: 36
Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges
David J. Birnkrant, Luca Bello, Russell J. Butterfield, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 4, pp. 403-420
Open Access | Times Cited: 26
Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls
Francesco Muntoni, James Signorovitch, Gautam Sajeev, et al.
Neuromuscular Disorders (2022) Vol. 32, Iss. 4, pp. 271-283
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top